Physiological and neural features and their relationship with subjective mystical experiences and depressive symptoms
depressive, depressive symptoms
It is argued that one of the predictors of outcome measures in psychedelic therapy is the intensity of mystical experiences reported by the participantsChanges in the magnitude of whole-brain fALFF following ketamine administration. (We also calculated the partial correlations between each feature and the RMEQ score while using the other features as covariates, to tease apart the contributions of cerebrovascular and systemic physiological features. We found PR, HbO fALFF, and HbR fALFF to have similar full correlations (0.57, − 0.47, − 0.43, respectively) as well as partial correlations (0.49, − 0.36, − 0.32, respectively; Lastly, we asked whether the change in QIDS scores were related to fALFF during the session. To this end, we modeled the change in QIDS scores as a function of fALFF during dosing sessions (in particular whether session fALFF was high or low, as defined by a median-split), session type (saline/ketamine), and the interaction between the two terms using Generalized Estimating Equations (GEEs). We found that the change in depressive symptoms not only depended on ketamine vs. saline but also on fALFF such that participants with higher fALFF showed a larger reduction in depressive symptoms after ketamine (Fig. 